China: FDA Panel to Weigh Grail's Galleri Test, a Pivotal Call for Liquid Biopsy Screening

An FDA advisory panel is set to weigh Grail's Galleri multi-cancer early detection test, a decision that could shape the future of liquid biopsy screening. The meeting comes as the biotech sector grapples with challenges including radiopharma toxicity issues and new regulatory guardrails in China's biotech innovation sector.